|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:DCBLD2-NIT2 (FusionGDB2 ID:21568) |
Fusion Gene Summary for DCBLD2-NIT2 |
Fusion gene summary |
Fusion gene information | Fusion gene name: DCBLD2-NIT2 | Fusion gene ID: 21568 | Hgene | Tgene | Gene symbol | DCBLD2 | NIT2 | Gene ID | 131566 | 56954 |
Gene name | discoidin, CUB and LCCL domain containing 2 | nitrilase family member 2 | |
Synonyms | CLCP1|ESDN | HEL-S-8a | |
Cytomap | 3q12.1|3 | 3q12.2 | |
Type of gene | protein-coding | protein-coding | |
Description | discoidin, CUB and LCCL domain-containing protein 21700055P21RikCUB, LCCL and coagulation factor V/VIII-homology domains protein 1coagulation factor V/VIII-homology domains protein 1endothelial and smooth muscle cell-derived neuropilin-like protein | omega-amidase NIT2Nit protein 2epididymis secretory sperm binding protein Li 8anitrilase homolog 2 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | Q96PD2 | Q9NQR4 | |
Ensembl transtripts involved in fusion gene | ENST00000326840, ENST00000326857, ENST00000469648, | ENST00000394140, | |
Fusion gene scores | * DoF score | 9 X 9 X 4=324 | 5 X 5 X 5=125 |
# samples | 10 | 6 | |
** MAII score | log2(10/324*10)=-1.6959938131099 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(6/125*10)=-1.05889368905357 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: DCBLD2 [Title/Abstract] AND NIT2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | DCBLD2(98526924)-NIT2(100071247), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | DCBLD2 | GO:0030308 | negative regulation of cell growth | 11447234 |
Hgene | DCBLD2 | GO:0042060 | wound healing | 11447234 |
Tgene | NIT2 | GO:0006107 | oxaloacetate metabolic process | 22674578 |
Tgene | NIT2 | GO:0006528 | asparagine metabolic process | 22674578 |
Tgene | NIT2 | GO:0006541 | glutamine metabolic process | 22674578 |
Fusion gene breakpoints across DCBLD2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across NIT2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | THCA | TCGA-FY-A4B3 | DCBLD2 | chr3 | 98526924 | - | NIT2 | chr3 | 100071247 | + |
Top |
Fusion Gene ORF analysis for DCBLD2-NIT2 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000326840 | ENST00000394140 | DCBLD2 | chr3 | 98526924 | - | NIT2 | chr3 | 100071247 | + |
In-frame | ENST00000326857 | ENST00000394140 | DCBLD2 | chr3 | 98526924 | - | NIT2 | chr3 | 100071247 | + |
intron-3CDS | ENST00000469648 | ENST00000394140 | DCBLD2 | chr3 | 98526924 | - | NIT2 | chr3 | 100071247 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000326840 | DCBLD2 | chr3 | 98526924 | - | ENST00000394140 | NIT2 | chr3 | 100071247 | + | 3878 | 2033 | 258 | 2279 | 673 |
ENST00000326857 | DCBLD2 | chr3 | 98526924 | - | ENST00000394140 | NIT2 | chr3 | 100071247 | + | 3515 | 1670 | 0 | 1916 | 638 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000326840 | ENST00000394140 | DCBLD2 | chr3 | 98526924 | - | NIT2 | chr3 | 100071247 | + | 0.000992478 | 0.9990075 |
ENST00000326857 | ENST00000394140 | DCBLD2 | chr3 | 98526924 | - | NIT2 | chr3 | 100071247 | + | 0.000767919 | 0.99923205 |
Top |
Fusion Genomic Features for DCBLD2-NIT2 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
DCBLD2 | chr3 | 98526924 | - | NIT2 | chr3 | 100071247 | + | 0.039366044 | 0.96063393 |
DCBLD2 | chr3 | 98526924 | - | NIT2 | chr3 | 100071247 | + | 0.039366044 | 0.96063393 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for DCBLD2-NIT2 |
Go to FGviewer for the breakpoints of chr3:98526924-chr3:100071247 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
DCBLD2 | NIT2 |
FUNCTION: Has omega-amidase activity (PubMed:22674578, PubMed:19595734). The role of omega-amidase is to remove potentially toxic intermediates by converting 2-oxoglutaramate and 2-oxosuccinamate to biologically useful 2-oxoglutarate and oxaloacetate, respectively (PubMed:19595734). {ECO:0000269|PubMed:19595734, ECO:0000269|PubMed:22674578}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326840 | - | 13 | 16 | 463_466 | 556.6666666666666 | 776.0 | Compositional bias | Note=Poly-Pro |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326857 | - | 13 | 16 | 463_466 | 556.6666666666666 | 790.0 | Compositional bias | Note=Poly-Pro |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326840 | - | 13 | 16 | 187_285 | 556.6666666666666 | 776.0 | Domain | LCCL |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326840 | - | 13 | 16 | 72_186 | 556.6666666666666 | 776.0 | Domain | CUB |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326857 | - | 13 | 16 | 187_285 | 556.6666666666666 | 790.0 | Domain | LCCL |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326857 | - | 13 | 16 | 72_186 | 556.6666666666666 | 790.0 | Domain | CUB |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326840 | - | 13 | 16 | 67_528 | 556.6666666666666 | 776.0 | Topological domain | Extracellular |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326857 | - | 13 | 16 | 67_528 | 556.6666666666666 | 790.0 | Topological domain | Extracellular |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326840 | - | 13 | 16 | 529_549 | 556.6666666666666 | 776.0 | Transmembrane | Helical |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326857 | - | 13 | 16 | 529_549 | 556.6666666666666 | 790.0 | Transmembrane | Helical |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326840 | - | 13 | 16 | 550_775 | 556.6666666666666 | 776.0 | Topological domain | Cytoplasmic |
Hgene | DCBLD2 | chr3:98526924 | chr3:100071247 | ENST00000326857 | - | 13 | 16 | 550_775 | 556.6666666666666 | 790.0 | Topological domain | Cytoplasmic |
Tgene | NIT2 | chr3:98526924 | chr3:100071247 | ENST00000394140 | 6 | 10 | 4_248 | 194.66666666666666 | 277.0 | Domain | CN hydrolase |
Top |
Fusion Gene Sequence for DCBLD2-NIT2 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>In-frame_ENST00000326840_ENST00000394140_TCGA-FY-A4B3_DCBLD2_chr3_98526924_-_NIT2_chr3_100071247_length(transcript)=3878nt_BP=2033nt GCCTGCCAGCTAGCCGGAGCCGCGGGTGAGCGCGGCGAGCGGCGACCCTGGTGAGGAGCGCGGCGCGGGAGGCACGTTCCTTAGCTCCGC CGCGGCCGTCCTCCGCGGCTCGAGGACTCCGCTTCCTTCCCTCCCCTCCCCTGCGCTCCGGCCTGGGGTCTCGGCGCGGGGAGCGGAGGG AAGGGACGAAGGAGGAGTAGGTGAAAGCGGGGTGAGGGGCGGAAGGGTCCCGGCGCGGGGTGAGGCGAGGGCTGCCTCTTGTTCTCCCGC CGCTGCCGCCGTCTCCTGGTCGGGTGCCGCGGCCAGAGGCGCGCGGGGCTGCCGAGGCACCCGCACTATGCAGGCAGACTGCCGGCCGCC GCGATGGCGAGCCGGGCGGTGGTGAGAGCCAGGCGCTGCCCGCAGTGTCCCCAAGTCCGGGCCGCGGCCGCCGCCCCCGCCTGGGCCGCG CTCCCCCTCTCCCGCTCCCTCCCTCCCTGCTCCAACTCCTCCTCCTTCTCCATGCCTCTGTTCCTCCTGCTCTTACTTGTCCTGCTCCTG CTGCTCGAGGACGCTGGAGCCCAGCAAGGTGATGGATGTGGACACACTGTACTAGGCCCTGAGAGTGGAACCCTTACATCCATAAACTAC CCACAGACCTATCCCAACAGCACTGTTTGTGAATGGGAGATCCGTGTAAAGATGGGAGAGAGAGTTCGCATCAAATTTGGTGACTTTGAC ATTGAAGATTCTGATTCTTGTCACTTTAATTACTTGAGAATTTATAATGGAATTGGAGTCAGCAGAACTGAAATAGGCAAATACTGTGGT CTGGGGTTGCAAATGAACCATTCAATTGAATCAAAAGGCAATGAAATCACATTGCTGTTCATGAGTGGAATCCATGTTTCTGGACGCGGA TTTTTGGCCTCATACTCTGTTATAGATAAACAAGATCTAATTACTTGTTTGGACACTGCATCCAATTTTTTGGAACCTGAGTTCAGTAAG TACTGCCCAGCTGGTTGTCTGCTTCCTTTTGCTGAGATATCTGGAACAATTCCTCATGGATATAGAGATTCCTCGCCATTGTGCATGGCT GGTGTGCATGCAGGAGTAGTGTCAAACACGTTGGGCGGCCAAATCAGTGTTGTAATTAGTAAAGGTATCCCCTATTATGAAAGTTCTTTG GCTAACAACGTCACATCTGTGGTGGGACACTTATCTACAAGTCTTTTTACATTTAAGACAAGTGGATGTTATGGAACACTGGGGATGGAG TCTGGTGTGATCGCGGATCCTCAAATAACAGCATCATCTGTGCTGGAGTGGACTGACCACACAGGGCAAGAGAACAGTTGGAAACCCAAA AAAGCCAGGCTGAAAAAACCTGGACCGCCTTGGGCTGCTTTTGCCACTGATGAATACCAGTGGTTACAAATAGATTTGAATAAGGAAAAG AAAATAACAGGCATTATAACCACTGGATCCACCATGGTGGAGCACAATTACTATGTGTCTGCCTACAGAATCCTGTACAGTGATGATGGG CAGAAATGGACTGTGTACAGAGAGCCTGGTGTGGAGCAAGATAAGATATTTCAAGGAAACAAAGATTATCACCAGGATGTGCGTAATAAC TTTTTGCCACCAATTATTGCACGTTTTATTAGAGTGAATCCTACCCAATGGCAGCAGAAAATTGCCATGAAAATGGAGCTGCTCGGATGT CAGTTTATTCCTAAAGGTCGTCCTCCAAAACTTACTCAACCTCCACCTCCTCGGAACAGCAATGACCTCAAAAACACTACAGCCCCTCCA AAAATAGCCAAAGGTCGTGCCCCAAAATTTACGCAACCACTACAACCTCGCAGTAGCAATGAATTTCCTGCACAGACAGAACAAACAACT GCCAGTCCTGATATCAGAAATACTACCGTAACTCCAAATGTAACCAAAGATGTAGCGCTGGCTGCAGTTCTTGTCCCTGTGCTGGTCATG GTCCTCACTACTCTCATTCTCATATTAGTGTGTGCTTGGCACTGGAGAAACAGGGCTGTTGATAATCAGGTGTATGTGGCCACAGCCTCT CCTGCCCGGGATGACAAAGCCTCCTATGTTGCCTGGGGACACAGCACCGTGGTGAACCCTTGGGGGGAGGTTCTAGCCAAAGCTGGCACA GAAGAAGCAATCGTGTATTCAGACATAGACCTGAAGAAGCTGGCTGAAATACGCCAGCAAATCCCCGTTTTTAGACAGAAGCGATCAGAC CTCTATGCTGTGGAGATGAAAAAGCCCTAAAGTTTATGTTTCTAATGTGTCACAGAATAGGACGATATGATTCTACAACATAATCAACTC CCTATTAAATTCTTTAATGAAGATTTTTTTTTTAATTCGGCCTTGTCCTTCCTAGGTTCTCTATTGAGATGAGAAAGCCTCATTATGCTG ACATTTTCCACGCCACATTAAATAGTTAAAAAGGATGCAGCCTGGAGCCAGAGAGCAGAAAGCTGGGCTGGTTCTGAAGCTTCTTCCATA CTTAAGTTGCCTCCAAGCAGTTTGTGAAAGTATCAGATCTTGGTATCCTGGTGATTGATTCACCTAATATAAATATATTTGTGTCATGAA CCTCTTATCCCGTTGCTGGAGTTGTAATCTCCATCATCTAGAAAACGTGGTCTGGTGCTATTCTTTTCCAAGCAGTACCTTGAAGTTCCA TTTTTGGTTCATGAGTAGCTATAGAACGCAAGGTGATACATCTTTGGTGTTTGCCAGAGAAGTTGGCAGCCCCACCCCTCCTACCAGCCT TTGCACTCTTCAAATTTAAAAAGGAGCTACTTATCAACCCCAGGCCCTTCTGGTCTTAGAGGAAGGACTGGGCCAACAAAGAGCACCATG GGAGAATGGCAGTGGTGGCATTTAGTGAAGACAATTTAGTATGAATGTCTGCAAAAGATTTTTTTGATAGCGTTGAGTGTCTGAAAGTCC CATTATTTTTCTTTTTTCTTTTTCCCCAGTAACACTTTCTAGCTCCACGGATAAGGAATCACTGAACCTAGTAGTTCTTAGACAGCTTGG TTTGAGAATCCTTTTGCGGTTAAAAATTAGGGACTGAGCCAGGCGCAGTAGCATGCGCCTGTAGTCCTAGCCACATTGGAGGCTGAGGTA GGAGGATCCCTTGAGTCCACAAGTTTGAGTTCAGCCAGAGACCCTATCTCACTATATATATGTATCTCAAAGACTTCAATGGGTTTTTGC TTACATGGGCCAGTAATTGTTGAACAACCAGCTATTTGAGAAAAAGCCCTGATTTTGCTGCTTTTCATGGTGTAAATACTTAACCATGGC TGAGTTTGAGCTATCTGCATGACACCTCTAAACACAGAGTTGGGAATAGATGTGCACAATCAGCTCTGGGGAGCTGGTGCAATCCTGCCC TAGCACACCACTGGTTTAAGATAGATATATCATATAGATATTTACCATTTACCATATTGGAAAGTAAAATGGAGAAAAATTTAAAACACA AGATACATGAGCACACATTCCATTAGCTATTAAGGTGATGGACACGGTGTCCAAATGACACGGTGTCATTTAACTTCTGGAAAACAACAC TGTGTACTGAGAACAAGAGAAAGACAAATGACTTTTTTAAATTAAGTTTTTAATTTACAATTGATGCATAATTTTACTTTAAAAAAATAA GTGTGCAATTTGGTAAACTTTGACATATACAGCTATAAACCACTCCAATCAAGATAACATATTTACCACCCCCAACAGTTTCCATGTGCT GTATTATAATCCCTCTGGCTAGTCCTTTGTCAATCACTGATAAATTTTATTACTATAGATTAGCTTGCATTTTCTAAAATTATATAAAAA >In-frame_ENST00000326840_ENST00000394140_TCGA-FY-A4B3_DCBLD2_chr3_98526924_-_NIT2_chr3_100071247_length(amino acids)=673AA_start in transcript=258_stop in transcript=2279 MFSRRCRRLLVGCRGQRRAGLPRHPHYAGRLPAAAMASRAVVRARRCPQCPQVRAAAAAPAWAALPLSRSLPPCSNSSSFSMPLFLLLLL VLLLLLEDAGAQQGDGCGHTVLGPESGTLTSINYPQTYPNSTVCEWEIRVKMGERVRIKFGDFDIEDSDSCHFNYLRIYNGIGVSRTEIG KYCGLGLQMNHSIESKGNEITLLFMSGIHVSGRGFLASYSVIDKQDLITCLDTASNFLEPEFSKYCPAGCLLPFAEISGTIPHGYRDSSP LCMAGVHAGVVSNTLGGQISVVISKGIPYYESSLANNVTSVVGHLSTSLFTFKTSGCYGTLGMESGVIADPQITASSVLEWTDHTGQENS WKPKKARLKKPGPPWAAFATDEYQWLQIDLNKEKKITGIITTGSTMVEHNYYVSAYRILYSDDGQKWTVYREPGVEQDKIFQGNKDYHQD VRNNFLPPIIARFIRVNPTQWQQKIAMKMELLGCQFIPKGRPPKLTQPPPPRNSNDLKNTTAPPKIAKGRAPKFTQPLQPRSSNEFPAQT EQTTASPDIRNTTVTPNVTKDVALAAVLVPVLVMVLTTLILILVCAWHWRNRAVDNQVYVATASPARDDKASYVAWGHSTVVNPWGEVLA -------------------------------------------------------------- >In-frame_ENST00000326857_ENST00000394140_TCGA-FY-A4B3_DCBLD2_chr3_98526924_-_NIT2_chr3_100071247_length(transcript)=3515nt_BP=1670nt ATGGCGAGCCGGGCGGTGGTGAGAGCCAGGCGCTGCCCGCAGTGTCCCCAAGTCCGGGCCGCGGCCGCCGCCCCCGCCTGGGCCGCGCTC CCCCTCTCCCGCTCCCTCCCTCCCTGCTCCAACTCCTCCTCCTTCTCCATGCCTCTGTTCCTCCTGCTCTTACTTGTCCTGCTCCTGCTG CTCGAGGACGCTGGAGCCCAGCAAGGTGATGGATGTGGACACACTGTACTAGGCCCTGAGAGTGGAACCCTTACATCCATAAACTACCCA CAGACCTATCCCAACAGCACTGTTTGTGAATGGGAGATCCGTGTAAAGATGGGAGAGAGAGTTCGCATCAAATTTGGTGACTTTGACATT GAAGATTCTGATTCTTGTCACTTTAATTACTTGAGAATTTATAATGGAATTGGAGTCAGCAGAACTGAAATAGGCAAATACTGTGGTCTG GGGTTGCAAATGAACCATTCAATTGAATCAAAAGGCAATGAAATCACATTGCTGTTCATGAGTGGAATCCATGTTTCTGGACGCGGATTT TTGGCCTCATACTCTGTTATAGATAAACAAGATCTAATTACTTGTTTGGACACTGCATCCAATTTTTTGGAACCTGAGTTCAGTAAGTAC TGCCCAGCTGGTTGTCTGCTTCCTTTTGCTGAGATATCTGGAACAATTCCTCATGGATATAGAGATTCCTCGCCATTGTGCATGGCTGGT GTGCATGCAGGAGTAGTGTCAAACACGTTGGGCGGCCAAATCAGTGTTGTAATTAGTAAAGGTATCCCCTATTATGAAAGTTCTTTGGCT AACAACGTCACATCTGTGGTGGGACACTTATCTACAAGTCTTTTTACATTTAAGACAAGTGGATGTTATGGAACACTGGGGATGGAGTCT GGTGTGATCGCGGATCCTCAAATAACAGCATCATCTGTGCTGGAGTGGACTGACCACACAGGGCAAGAGAACAGTTGGAAACCCAAAAAA GCCAGGCTGAAAAAACCTGGACCGCCTTGGGCTGCTTTTGCCACTGATGAATACCAGTGGTTACAAATAGATTTGAATAAGGAAAAGAAA ATAACAGGCATTATAACCACTGGATCCACCATGGTGGAGCACAATTACTATGTGTCTGCCTACAGAATCCTGTACAGTGATGATGGGCAG AAATGGACTGTGTACAGAGAGCCTGGTGTGGAGCAAGATAAGATATTTCAAGGAAACAAAGATTATCACCAGGATGTGCGTAATAACTTT TTGCCACCAATTATTGCACGTTTTATTAGAGTGAATCCTACCCAATGGCAGCAGAAAATTGCCATGAAAATGGAGCTGCTCGGATGTCAG TTTATTCCTAAAGGTCGTCCTCCAAAACTTACTCAACCTCCACCTCCTCGGAACAGCAATGACCTCAAAAACACTACAGCCCCTCCAAAA ATAGCCAAAGGTCGTGCCCCAAAATTTACGCAACCACTACAACCTCGCAGTAGCAATGAATTTCCTGCACAGACAGAACAAACAACTGCC AGTCCTGATATCAGAAATACTACCGTAACTCCAAATGTAACCAAAGATGTAGCGCTGGCTGCAGTTCTTGTCCCTGTGCTGGTCATGGTC CTCACTACTCTCATTCTCATATTAGTGTGTGCTTGGCACTGGAGAAACAGGGCTGTTGATAATCAGGTGTATGTGGCCACAGCCTCTCCT GCCCGGGATGACAAAGCCTCCTATGTTGCCTGGGGACACAGCACCGTGGTGAACCCTTGGGGGGAGGTTCTAGCCAAAGCTGGCACAGAA GAAGCAATCGTGTATTCAGACATAGACCTGAAGAAGCTGGCTGAAATACGCCAGCAAATCCCCGTTTTTAGACAGAAGCGATCAGACCTC TATGCTGTGGAGATGAAAAAGCCCTAAAGTTTATGTTTCTAATGTGTCACAGAATAGGACGATATGATTCTACAACATAATCAACTCCCT ATTAAATTCTTTAATGAAGATTTTTTTTTTAATTCGGCCTTGTCCTTCCTAGGTTCTCTATTGAGATGAGAAAGCCTCATTATGCTGACA TTTTCCACGCCACATTAAATAGTTAAAAAGGATGCAGCCTGGAGCCAGAGAGCAGAAAGCTGGGCTGGTTCTGAAGCTTCTTCCATACTT AAGTTGCCTCCAAGCAGTTTGTGAAAGTATCAGATCTTGGTATCCTGGTGATTGATTCACCTAATATAAATATATTTGTGTCATGAACCT CTTATCCCGTTGCTGGAGTTGTAATCTCCATCATCTAGAAAACGTGGTCTGGTGCTATTCTTTTCCAAGCAGTACCTTGAAGTTCCATTT TTGGTTCATGAGTAGCTATAGAACGCAAGGTGATACATCTTTGGTGTTTGCCAGAGAAGTTGGCAGCCCCACCCCTCCTACCAGCCTTTG CACTCTTCAAATTTAAAAAGGAGCTACTTATCAACCCCAGGCCCTTCTGGTCTTAGAGGAAGGACTGGGCCAACAAAGAGCACCATGGGA GAATGGCAGTGGTGGCATTTAGTGAAGACAATTTAGTATGAATGTCTGCAAAAGATTTTTTTGATAGCGTTGAGTGTCTGAAAGTCCCAT TATTTTTCTTTTTTCTTTTTCCCCAGTAACACTTTCTAGCTCCACGGATAAGGAATCACTGAACCTAGTAGTTCTTAGACAGCTTGGTTT GAGAATCCTTTTGCGGTTAAAAATTAGGGACTGAGCCAGGCGCAGTAGCATGCGCCTGTAGTCCTAGCCACATTGGAGGCTGAGGTAGGA GGATCCCTTGAGTCCACAAGTTTGAGTTCAGCCAGAGACCCTATCTCACTATATATATGTATCTCAAAGACTTCAATGGGTTTTTGCTTA CATGGGCCAGTAATTGTTGAACAACCAGCTATTTGAGAAAAAGCCCTGATTTTGCTGCTTTTCATGGTGTAAATACTTAACCATGGCTGA GTTTGAGCTATCTGCATGACACCTCTAAACACAGAGTTGGGAATAGATGTGCACAATCAGCTCTGGGGAGCTGGTGCAATCCTGCCCTAG CACACCACTGGTTTAAGATAGATATATCATATAGATATTTACCATTTACCATATTGGAAAGTAAAATGGAGAAAAATTTAAAACACAAGA TACATGAGCACACATTCCATTAGCTATTAAGGTGATGGACACGGTGTCCAAATGACACGGTGTCATTTAACTTCTGGAAAACAACACTGT GTACTGAGAACAAGAGAAAGACAAATGACTTTTTTAAATTAAGTTTTTAATTTACAATTGATGCATAATTTTACTTTAAAAAAATAAGTG TGCAATTTGGTAAACTTTGACATATACAGCTATAAACCACTCCAATCAAGATAACATATTTACCACCCCCAACAGTTTCCATGTGCTGTA TTATAATCCCTCTGGCTAGTCCTTTGTCAATCACTGATAAATTTTATTACTATAGATTAGCTTGCATTTTCTAAAATTATATAAAAATGA >In-frame_ENST00000326857_ENST00000394140_TCGA-FY-A4B3_DCBLD2_chr3_98526924_-_NIT2_chr3_100071247_length(amino acids)=638AA_start in transcript=0_stop in transcript=1916 MASRAVVRARRCPQCPQVRAAAAAPAWAALPLSRSLPPCSNSSSFSMPLFLLLLLVLLLLLEDAGAQQGDGCGHTVLGPESGTLTSINYP QTYPNSTVCEWEIRVKMGERVRIKFGDFDIEDSDSCHFNYLRIYNGIGVSRTEIGKYCGLGLQMNHSIESKGNEITLLFMSGIHVSGRGF LASYSVIDKQDLITCLDTASNFLEPEFSKYCPAGCLLPFAEISGTIPHGYRDSSPLCMAGVHAGVVSNTLGGQISVVISKGIPYYESSLA NNVTSVVGHLSTSLFTFKTSGCYGTLGMESGVIADPQITASSVLEWTDHTGQENSWKPKKARLKKPGPPWAAFATDEYQWLQIDLNKEKK ITGIITTGSTMVEHNYYVSAYRILYSDDGQKWTVYREPGVEQDKIFQGNKDYHQDVRNNFLPPIIARFIRVNPTQWQQKIAMKMELLGCQ FIPKGRPPKLTQPPPPRNSNDLKNTTAPPKIAKGRAPKFTQPLQPRSSNEFPAQTEQTTASPDIRNTTVTPNVTKDVALAAVLVPVLVMV LTTLILILVCAWHWRNRAVDNQVYVATASPARDDKASYVAWGHSTVVNPWGEVLAKAGTEEAIVYSDIDLKKLAEIRQQIPVFRQKRSDL -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for DCBLD2-NIT2 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for DCBLD2-NIT2 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for DCBLD2-NIT2 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | DCBLD2 | C0024623 | Malignant neoplasm of stomach | 1 | CTD_human |
Hgene | DCBLD2 | C0032460 | Polycystic Ovary Syndrome | 1 | CTD_human |
Hgene | DCBLD2 | C0038356 | Stomach Neoplasms | 1 | CTD_human |
Hgene | DCBLD2 | C1136382 | Sclerocystic Ovaries | 1 | CTD_human |
Hgene | DCBLD2 | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human |